Figure 33-2

Figure 33.2. Estimated absolute survival advantages with prolonged polychemotherapy for women ages 50-69 years with good, intermediate, and poor prognosis. (Reproduced with permission from the Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials.)